Brooks Automation

Investor Overview

June 2020

Safe Harbor Statement

"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. Further discussions of risk factors are available in the Company's most recent SEC filings, including the annual report on Form 10-K for the fiscal year ended September 30, 2019 and any subsequent quarterly reports on Form 10-Q. The Company assumes no obligation to update the information in this presentation.

Regulation G

This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Brooks business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant GAAP amount are provided as a separate presentation on the Company's website.

All financial projections throughout this presentation, other than ROIC, exclude amortization of intangibles, restructuring expense and other special charges.

© 2020 Brooks Automation, Inc. • Proprietary Information

Driving Performance. Delivering Profitable Growth.

- Brooks overview

- Building on two strong platforms – Life Sciences and Semiconductor

- Model for profitable growth

© 2020 Brooks Automation, Inc. • Proprietary Information

Brooks at a Glance:
Serving Global Life Sciences and Semiconductor Markets

Life Sciences

- ✓ Sample Management Products and Services
- ✓ Genomic Services

Semiconductor Solutions



- ✓ Wafer Automation
- ✓ Contamination Control
- ✓ Global Service Support

FY'19 $781M (+24% YtY)

~ 3,000 Global Employees

Sales in 50 Countries

NASDAQ: BRKS
Sept 30 Year-End

Annual Dividend
$0.40/share

© 2020 Brooks Automation, Inc. • Proprietary Information

Business in the COVID Environment

- ✓**Both Segments are deemed essential and operations have continued**
- ✓**Fundamentals of the business remain strong**
  - Leadership positions in both markets
  - Strong liquidity provides strategic flexibility
- ✓**Our momentum in the market remains strong with near-term caveats**
  - Semi Capex environment depends on decisions of the concentrated end-users and continuity of the industry supply chain
  - Life Sciences' pharma, biotech, and clinical markets are actively feeding our momentum, while academic research has not returned
- ✓**Maintaining investments**
  - Keep team in place, accelerating development, and extending our leadership

Accelerating a Strong Track Record of Growth and Margin Expansion

$M

Revenue



Gross Margin*



EPS*



* Non-GAAP financial measures – see reconciliation tables

© 2020 Brooks Automation, Inc. • Proprietary Information

Transformation to Higher Growth, Higher Margin Profile



© 2020 Brooks Automation, Inc. • Proprietary Information

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Building on two strong platforms – Life Sciences and Semiconductor
- Model for profitable growth

© 2020 Brooks Automation, Inc. • Proprietary Information

Building on Two Strong Platforms
Life Sciences

What We Do

Products - Sample Storage Infrastructure, Consumables and Instruments

Services – Genomics and Sample Storage Services

Our Value

Best-in-Class Solutions
- ✓ **Science**
- ✓ **Technology**

Quality & Integrity
- ✓ **Sample assets**
- ✓ **Expert analysis**

Efficiency in Workflow
- ✓ **Fast Turnaround Time**
- ✓ **Capital**

Revenue



© 2020 Brooks Automation, Inc. • Proprietary Information

Life Sciences – Diverse Revenue Profile Aligned for Higher Growth

Products 35%



Services 65%

Serving a $10B Market in Sample Storage and Genomics

- Discovery research
- Drug and biological drug development
- Clinical research and trials
- Precision medicine
- Regenerative medicine
- Cell and gene therapy
- Infectious disease research and treatment
- Agriculture

© 2020 Brooks Automation, Inc. • Proprietary Information

Revenue percentages based on FY2019 revenue of $334M which includes 10.5 months of GENEWIZ ownership

Cell and Gene Therapy (CGT) Growth Opportunity

Global Companies with Notable CGT Programs
(excl. major Pharma and Biotech)

>500

Brooks Life Science CGT Customers
(Institutional level)

>130

Brooks Life Science CGT Offerings

Cryo

GENEWIZ

Consumables

Brooks Life Science Total CGT Revenue
(80% YtY Growth)

FY'19 ~$20M

NOVARTIS · Kite · Spark THERAPEUTICS · CRISPR THERAPEUTICS · BIOMARIN

© 2020 Brooks Automation, Inc. • Proprietary Information

Our Expertise has Allowed Us to Win an Impressive Global Customer Base

Leading healthcare institutions depend on Brooks

© 2020 Brooks Automation, Inc. • Proprietary Information

Building on Two Strong Platforms
Semiconductor Solutions

What We Do

Wafer Level Automation

- Robotics and Systems

Contamination Control

- Carrier cleaning
- Reticle Stockers

Global Service and Support

Our Value

Enabling Process Advantages

- ✓ **Precision handling**
- ✓ **Productivity**
- ✓ **Reliability**
- ✓ **Process control**
- ✓ **Yield Enhancement**
- ✓ **Trusted partner**

Revenue



© 2020 Brooks Automation, Inc. • Proprietary Information

Semiconductor Equipment CAPEX Market Growth Driven by New Applications and Manufacturing Complexity

Market Drivers of Wafer Fab Equip. CAPEX

Volume Demand

- New chip factory lines
- Capacity build-out

Chip Complexity

Leading edge technology drives:

- More process steps
- Contamination vulnerability

Brooks Leads in Automation, Vacuum Environments, and Contamination Control

#1

Vacuum Automation Systems & Robots

#1

Carrier Cleaners & Reticle Stockers



#1

Advanced Packaging Solutions

Global Service

Enabling Customer Process Advantages

All Wafer Fabs

All Technology Nodes

Logic, Foundry & Memory

© 2020 Brooks Automation, Inc. • Proprietary Information

Leading Customers in High-Growth Segments



Device Manufacturers ~30%*	Equipment Manufacturers ~70%*	100%

© 2020 Brooks Automation, Inc. • Proprietary Information

* FY2019 revenue % based on management's internal estimates

Driving Performance. Delivering Profitable Growth.

- Brooks overview
- Building on two strong platforms – Life Sciences and Semiconductor
- Model for profitable growth

© 2020 Brooks Automation, Inc. • Proprietary Information

Consistent Strategy Going Forward

1. Extend leadership in core markets
2. Advance the rapid growth of Life Sciences with organic and acquisition investments
3. Drive margin expansion
4. Utilize balanced and disciplined capital deployment



© 2020 Brooks Automation, Inc. • Proprietary Information

FY 2022 Brooks Target Model

Life Sciences

- Revenue growth **$520M**
- CAGR from 2019 **16%**
- Gross Margin* target **45-48%**
- OPEX productivity

Operating Margins*	**15-18%**
% of Brooks revenue	**45%**

Semiconductor

- Revenue range **$580 - 680M**
- CAGR from 2019 **~12%**
- Gross Margin* target **42-44%**
- OPEX productivity



Operating Margins*	**20-22%**
% of Brooks revenue	**55%**

Brooks

Revenue CAGR from 2019
14%

Operating Margins*
19%

ROIC of
13%

© 2020 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measures - Projections exclude intangibles amortization, restructuring expense, and other special charges.

FY 2022 Target Model

	FY 2015	FY 2017	FY 2019	FY 2022 Goal
Total Revenue	$407M	$527M	$781M	**$1,100-1,200M**
Semi	*$339M*	*$379M*	*$447M*	**$580-680M**
Life Sciences	*$68M*	*$149M*	*$334M*	**$520M**
% of total	*17%*	*28%*	*43%*	**~45%**
Gross Margin*	34.1%	38.5%	41.9%	**~44-46%**
Operating Expenses*	34.9%	30.3%	30.3%	**26-27%**
% of Revenue				
Operating Income*	($3M)	$43M	$90M	**$200-240M**
% of Revenue	(0.8%)	8.2%	11.6%	**18%-20%**
EBITDA*	$18M	$68M	$128M	**$245-285M**
EPS*	$0.05	$0.44	$0.76	**$2.00-2.40**

* Non-GAAP financial measures – see reconciliation tables. Projections exclude intangibles amortization, restructuring expense, and other special charges.

© 2020 Brooks Automation, Inc. • Proprietary Information

Disciplined Capital Deployment Over Last 5 Years
Strong Cash Generation Affords Investment

CAPEX
~7%
- Low CAPEX operations
  - 2-3% of revenue historically
  - Expect 4-6% of revenue with GENEWIZ

Return Cash to Shareholders
~12%
- Dividends – $140M cumulative on $0.40 per share annually

~20%

Organic Growth
- Investment of ~$50M in R&D annually

~61%

M&A
- Priority in Life Sciences and opportunistic in Semi
- ROIC focus

© 2020 Brooks Automation, Inc. • Proprietary Information

Last 5 years = FY2015 - FY2019

Continuous Portfolio Enhancement for Value and Higher Growth

Acquisitions

Life Sciences	~$830M
Semi	~$115M

2011-2012

- RTS for $3M
- Nexus for $85M
- Crossing Automation for $59M
- Divested of Contract Manufacturing for $78M

2013-2014

- Matrical for $9M
- 22% of BioCision for $4M
- DMS for $32M
- Divested of Granville-Phillips instrumentation for $87M

2015-2016

- FluidX for $16M
- BioStorage Technologies for $125M
- Contact for $7M

2017-2018

- BioCision add'l $11M
- PBMMI for $34M
- FreezerPro software for $5M
- 4titude Ltd. for $66M
- BioSpeciMan for $5M
- Tec-Sem for $16M

2019 - 2020

- GENEWIZ for $450M
- **RURO for $15M**
- Divested Semi Cryogenics for $675M

9 years, 20 transactions, $945M, with ROIC focus

© 2019 Brooks Automation, Inc. • Proprietary Information

Guidance As Provided April 30, 2020
Continuing Operations

$M except EPS	Q2'19	Q3'19	Q4'19	Q1'20	Q2'20	Guidance Q3'20
Brooks Total Revenue	**$198**	**$204**	**$200**	**$210**	**$220**	**$200-215**
Semiconductor Solutions	*$113*	*$116*	*$106*	*$119*	*$125*	*$115-124*
Life Science	*$86*	*$88*	*$94*	*$92*	*$95*	*$85-91*
Adjusted EBITDA*	$33	$36	$31	$32	$35	$26-34
Non-GAAP EPS*	$0.17	$0.20	$0.24	$0.23	$0.25	$0.16 - $0.24
Dividends/share Returned to Shareholders	$0.10	$0.10	$0.10	$0.10	$0.10	$0.10**

** The Board of Directors has approved a dividend of $0.10 per share payable on June 26, 2020 to stockholders of record on June 6, 2020

* Non-GAAP financial measures – see reconciliation tables. Projections exclude intangibles amortization, restructuring expense, and other special charges.

© 2019 Brooks Automation, Inc. • Proprietary Information

IN SUMMARY

Two High Performance Businesses. Positioned for Profitable Growth and Further Investment

Two Strong Markets with Strong Leadership Positions

- ✓ **Semiconductor Equipment and Service**

- ✓ **Life Sciences Sample Management and Genomics**

Attractive Long Term Financial Model

- ✓ Two profitable growth businesses
- ✓ Significant operating leverage for increased profits & cash

Track Record of Effective Capital Deployment

- ✓ ROIC Focused
- ✓ Capturing opportunity for growth & value through acquisitions
- ✓ 10th year of dividends

Strong Performance in a Challenging Market Environment

- ✓ Fundamentals of the business remain strong for the long term
  - Leadership positions in our markets
  - Strong liquidity provides strategic flexibility
- ✓ Our momentum in the market remains strong with near-term caveats
- ✓ Maintaining investments now to keep team in place, accelerate development, and to extend our leadership during these turbulent times

© 2020 Brooks Automation, Inc. • Proprietary Information

Brooks

Non-GAAP Reconciliation Appendix

Non-GAAP Annual Operating Performance Continuing Operations

$ millions, except EPS

	FY15	FY16	FY17	FY18	FY19
Revenue	407	434	527	632	781
Gross profit*	139	161	203	253	327
*Gross profit margin**	*34.1 %*	*37.2 %*	*38.5 %*	*40.0 %*	*41.9 %*
R&D expenses	46	44	40	47	56
SG&A expenses*	96	104	120	141	181
Operating income *	(3)	13	43	65	90
*Operating margin**	*(0.8)%*	*2.9 %*	*8.2 %*	*10.3 %*	*11.6 %*
Other income (expense)	2	(1)	(2)	(11)	(22)
Tax benefit (provision)*	5	4	(10)	(9)	(13)
JV and noncontrolling interests*	(1)	(1)	(0)	-	-
Net income*	3	15	31	45	55
*Net income margin**	*0.8 %*	*3.4 %*	*5.9 %*	*7.2 %*	*7.1 %*
Diluted Non-GAAP EPS - Continuing Ops*	0.05	0.21	0.44	0.64	0.76
Adjusted EBITDA*	18	34	68	93	128

© 2019 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measures – see reconciliation tables within this appendix. Results shown on continuing operations basis.

Non-GAAP Segment Annual Operating Performance Continuing Operations

$ millions

Brooks Semiconductor Solutions

	FY15	FY16	FY17	FY18	FY19
Revenue	339	326	379	435	447
Gross profit*	118	121	147	178	185
*Gross profit margin**	*35.0 %*	*37.1 %*	*38.7 %*	*40.9 %*	*41.5 %*
Operating expenses	105	101	104	116	115
Operating income *	13	20	43	63	70
*Operating margin**	*4.0 %*	*6.1 %*	*11.3 %*	*14.4 %*	*15.6 %*

Brooks Life Sciences

	FY15	FY16	FY17	FY18	FY19
Revenue	68	108	149	197	334
Gross profit*	20	41	57	75	142
*Gross profit margin**	*29.8 %*	*37.5 %*	*38.0 %*	*38.0 %*	*42.4 %*
Operating expenses	37.1	(46)	53	71	121
Operating income *	(16.8)	(5)	3	4	21
*Operating margin**	*(24.6)%*	*(4.6)%*	*2.2 %*	*1.9 %*	*6.2 %*

© 2019 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measures – see reconciliation tables within this appendix. Results shown on continuing operations basis.

Non-GAAP Quarterly Operating Performance Continuing Operations

$ millions, except EPS

	Total Brooks				
	Q2'19	**Q3'19**	**Q4'19**	**Q1'20**	**Q2'20**
Revenue	198	204	199	210	220
Gross profit*	83	86	83	88	93
*Gross profit margin**	*42.0 %*	*42.4 %*	*41.8 %*	*41.6 %*	*42.2 %*
R&D expenses	14	14	15	14	15
SG&A expenses*	46	46	47	51	52
Operating income *	23	26	21	22	26
*Operating margin**	*11.8 %*	*12.7 %*	*10.6 %*	*10.5 %*	*11.7 %*
Other income (expense)	(8)	(8)	(1)	(0)	(2)
Tax benefit (provision)*	(3)	(3)	(4)	(5)	(5)
Net income*	12	14	17	17	18
*Net income margin**	*6.2 %*	*7.0 %*	*8.5 %*	*7.9 %*	*8.4 %*
Diluted Non-GAAP EPS - Continuing Ops*	0.17	0.20	0.23	0.23	0.25
Adjusted EBITDA*	33	36	31	32	35

© 2019 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measures – see reconciliation tables within this appendix. Results shown on continuing operations basis.

Non-GAAP Segment Quarterly Operating Performance Continuing Operations

$ millions

Brooks Semiconductor Solutions

	Q2'19	Q3'19	Q4'19	Q1'20	Q2'20
Revenue	113	116	105	119	125
Gross profit*	47	48	43	47	49
*Gross profit margin**	*41.6 %*	*41.7 %*	*41.1 %*	*39.6 %*	*39.5 %*
Operating expenses	28	28	30	32	33
Operating income *	19	20	14	15	17
*Operating margin**	*16.7 %*	*17.4 %*	*12.9 %*	*12.6 %*	*13.4 %*

Brooks Life Sciences

	Q2'19	Q3'19	Q4'19	Q1'20	Q2'20
Revenue	86	88	94	92	95
Gross profit*	36	38	40	41	44
*Gross profit margin**	*42.6 %*	*43.3 %*	*42.6 %*	*44.3 %*	*45.8 %*
Operating expenses	31	32	33	35	36
Operating income *	5	6	7	6	8
*Operating margin**	*5.9 %*	*7.0 %*	*7.2 %*	*6.5 %*	*8.5 %*

© 2019 Brooks Automation, Inc. • Proprietary Information

* Non-GAAP financial measures – see reconciliation tables within this appendix. Results shown on continuing operations basis.

GAAP to Non-GAAP Reconciliation
2015 - 2019 Total Brooks - Continuing Operations

$ millions, except EPS

	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019
Revenue	**407**	**434**	**527**	**632**	**781**
GAAP gross profit	**133**	**157**	**199**	**246**	**316**
Merger and acquisition costs	2	1	1	2	0
Amortization expense	4	4	4	5	10
Other Special Charges	-	-	-	-	0
Non-GAAP gross profit	**139**	**161**	**203**	**253**	**327**
Gross profit margin	*33%*	*36%*	*38%*	*39%*	*41%*
Non-GAAP gross profit margin	*34%*	*37%*	*39%*	*40%*	*42%*
GAAP operating expenses	**(155)**	**(174)**	**(185)**	**(215)**	**(270)**
Merger and acquisition costs	1	3	8	7	7
Amortization expense	8	11	13	19	25
Restructuring and related charges	5	10	3	1	2
Other Special Charges	-	1	-	-	-
Non-GAAP operating expenses	**(142)**	**(149)**	**(160)**	**(188)**	**(237)**
GAAP operating profit (loss)	**(23)**	**(17)**	**14**	**31**	**46**
Non-GAAP operating profit (loss)	(3)	13	43	65	90
Operating profit margin	*-6%*	*-4%*	*3%*	*5%*	*6%*
Non-GAAP operating profit margin	*-1%*	*3%*	*8%*	*10%*	*12%*
GAAP net income (loss)	**(13)**	**(85)**	**11**	**68**	**10**
Merger and acquisition costs	2	4	9	9	7
Amortization expense	12	15	17	24	35
Restructuring and related charges	5	10	3	1	2
Other Special Charges	3	1	(1)	(0)	-
Loss on extinguishment of debt	-	-	-	-	14
Tax related adjustments	(0)	77	(4)	(44)	2
Tax effect of adjustments	(6)	(6)	(3)	(13)	(14)
Non-GAAP net income	**3**	**15**	**31**	**45**	**55**
Diluted earnings per share	*(0.18)*	*(1.25)*	*0.15*	*0.95*	*0.13*
Non-GAAP diluted earnings per share	*0.05*	*0.21*	*0.44*	*0.64*	*0.76*

© 2019 Brooks Automation, Inc. • Proprietary Information

GAAP to Non-GAAP Reconciliation
Q2'19 – Q2'20 Total Brooks - Continuing Operations

$ millions, except EPS

	Q2 FY19	Q3 FY19	Q4 FY19	Q1 FY20	Q2 FY20
Revenue	**198**	**204**	**199**	**210**	**220**
GAAP gross profit	**81**	**84**	**80**	**85**	**90**
Merger and acquisition costs	-	-	-	-	-
Amortization expense	3	3	3	3	3
Restructuring and related charges	-	-	0	-	-
Non-GAAP gross profit	**83**	**86**	**83**	**88**	**93**
Gross profit margin	*41%*	*41%*	*40%*	*40%*	*41%*
Non-GAAP gross profit margin	*42%*	*42%*	*42%*	*42%*	*42%*
GAAP operating expenses	**(67)**	**(67)**	**(70)**	**(74)**	**(76)**
Merger and acquisition costs	0	0	0	0	0
Amortization expense	7	6	6	8	8
Restructuring and related charges	0	0	1	1	1
Non-GAAP operating expenses	**(60)**	**(60)**	**(62)**	**(66)**	**(67)**
GAAP operating profit	**14**	**16**	**11**	**11**	**15**
Non-GAAP operating profit	23	26	21	22	26
Operating profit margin	*7%*	*8%*	*5%*	*5%*	*7%*
Non-GAAP operating profit margin	*12%*	*13%*	*11%*	*10%*	*12%*
GAAP net income (loss)	**(3)**	**1**	**5**	**13**	**9**
Merger and acquisition costs	0	0	0	0	0
Amortization expense	9	9	9	11	10
Restructuring and related charges	0	0	1	1	1
Loss on extinguishment of debt	9	-	5	-	-
Tax related adjustments	1	5	(0)	(5)	1
Tax effect of adjustments	(5)	(1)	(4)	(3)	(3)
Non-GAAP net income	**12**	**14**	**17**	**17**	**18**
Diluted earnings per share	*(0.04)*	*0.01*	*0.07*	*0.18*	*0.12*
Non-GAAP diluted earnings per share	*0.17*	*0.20*	*0.23*	*0.23*	*0.25*

© 2019 Brooks Automation, Inc. • Proprietary Information

GAAP to Non-GAAP Reconciliation
Q2'19 – Q2'20 Segments – Continuing Operations

$ millions

	Q2 FY19	Q3 FY19	Q4 FY19	Q1 FY20	Q2 FY20
BSSG					
Revenue	**$ 113**	**$ 116**	**$ 105**	**$ 119**	**$ 125**
GAAP gross profit	**46**	**47**	**42**	**46**	**49**
Merger and acquisition costs	-	-	-	(0)	(0)
Amortization expense	1	1	1	1	1
Non-GAAP gross profit	**47**	**48**	**43**	**47**	**49**
Gross profit margin	*41%*	*41%*	*40%*	*39%*	*39%*
Non-GAAP gross profit margin	*42%*	*42%*	*41%*	*40%*	*40%*
Operating expenses	**(28)**	**(28)**	**(30)**	**(32)**	**(33)**
GAAP operating profit	**18**	**19**	**13**	**14**	**16**
Non-GAAP operating profit	**19**	**20**	**14**	**15**	**17**
Operating profit margin	*16%*	*17%*	*12%*	*12%*	*13%*
Non-GAAP operating profit margin	*17%*	*17%*	*13%*	*13%*	*13%*
BLS					
Revenue	**$ 86**	**$ 88**	**$ 94**	**$ 92**	**$ 95**
GAAP gross profit	**35**	**36**	**38**	**39**	**42**
Merger and acquisition costs	-	-	-	-	-
Amortization expense	2	2	2	2	2
Other special charges	-	-	0	-	-
Non-GAAP gross profit	**36**	**38**	**40**	**41**	**44**
Gross profit margin	*40%*	*41%*	*40%*	*42%*	*44%*
Non-GAAP gross profit margin	*43%*	*43%*	*43%*	*44%*	*46%*
Operating expenses	**(31)**	**(32)**	**(33)**	**(35)**	**(36)**
GAAP operating profit	**3**	**4**	**5**	**4**	**6**
Non-GAAP operating profit	**5**	**6**	**7**	**6**	**8**
Operating profit margin	*4%*	*5%*	*5%*	*4%*	*6%*
Non-GAAP operating profit margin	*6%*	*7%*	*7%*	*7%*	*9%*

© 2019 Brooks Automation, Inc. • Proprietary Information

GAAP to Non-GAAP Reconciliation
2015 - 2019 Segments – Continuing Operations

$ millions

	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019
BSSG					
Revenue	**$ 339**	**$ 326**	**$ 379**	**$ 435**	**$ 447**
GAAP gross profit	**115**	**118**	**144**	**174**	**182**
Merger and acquisition costs	1	1	0	1	-
Amortization expense	3	3	3	3	4
Non-GAAP gross profit	**118**	**121**	**147**	**178**	**185**
Gross profit margin	*34%*	*36%*	*38%*	*40%*	*41%*
Non-GAAP gross profit margin	*35%*	*37%*	*39%*	*41%*	*41%*
Operating expenses	**(105)**	**(101)**	**(104)**	**(116)**	**(115)**
GAAP operating profit	**10**	**17**	**40**	**58**	**66**
Non-GAAP operating profit	13	20	43	63	70
Operating profit margin	*3%*	*5%*	*11%*	*13%*	*15%*
Non-GAAP operating profit margin	*4%*	*6%*	*11%*	*14%*	*16%*
BLS					
Revenue	**$ 68**	**$ 108**	**$ 149**	**$ 197**	**$ 334**
GAAP gross profit	**18**	**39**	**55**	**72**	**135**
Merger and acquisition costs	1	-	0	1	-
Amortization expense	2	1	1	1	7
Other special charges	-	-	-	-	0
Non-GAAP gross profit	**20**	**41**	**57**	**75**	**142**
Gross profit margin	*26%*	*36%*	*37%*	*37%*	*40%*
Non-GAAP gross profit margin	*30%*	*37%*	*38%*	*38%*	*42%*
Operating expenses	**(37)**	**(46)**	**(53)**	**(71)**	**(121)**
GAAP operating profit (loss)	**(19)**	**(6)**	**1**	**1**	**14**
Non-GAAP operating profit (loss)	(17)	(5)	3	4	21
Operating profit margin	*-28%*	*-6%*	*1%*	*1%*	*4%*
Non-GAAP operating profit margin	*-25%*	*-5%*	*2%*	*2%*	*6%*

© 2019 Brooks Automation, Inc. • Proprietary Information

Net Income Reconciliation to Adjusted EBITDA 2015 to 2019 – Continuing Operations

$ millions

	FY'15	FY'16	FY'17	FY'18	FY'19
Net income (loss) attributable to Brooks Automation, Inc.	14.2	(69.5)	62.6	116.6	437.4
Income from discontinued operations, net of tax	(26.7)	(16.0)	(51.9)	(48.7)	(427.9)
Net income from continuing operations	**(12.5)**	**(85.5)**	**10.7**	**67.8**	**9.6**
Adjustments:					
Interest income	(0.9)	(0.5)	(0.5)	(1.9)	(1.4)
Interest expense	0.4	0.2	0.4	9.5	22.2
Income tax provision (benefit)	(11.3)	66.3	3.4	(47.3)	(0.1)
Depreciation	11.4	12.2	10.4	12.5	19.3
Amortization of intangible assets	12.1	14.8	17.1	24.2	35.2
Restructuring related charges	-	-	-	-	0.3
Loss on extinguishment of debt	-	-	-	-	14.3
EBITDA-from Continuing Operations	**(0.8)**	**7.5**	**41.5**	**64.9**	**99.3**
Non-GAAP adjustments:					
Purchase accounting impact on inventory and contracts acquired	1.5	0.6	0.5	1.9	0.2
Stock-based compensation	11.9	11.3	16.6	18.9	19.5
Restructuring & related charges	4.9	10.2	3.1	0.7	1.9
Merger and acquisition costs / Other	0.7	4.2	6.7	6.9	6.7
Adjusted EBITDA - from Continuing Operations	**18.1**	**33.8**	**68.5**	**93.3**	**127.6**

© 2019 Brooks Automation, Inc. • Proprietary Information

Net Income Reconciliation to Adjusted EBITDA
Q2'19 – Q2'20 – Continuing Operations

$ millions

	Q2'19	Q3'19	Q4'19	Q1'20	Q2'20
Net income attributable to Brooks Automation, Inc.	3.4	7.3	412.3	13.1	9.1
(Income) loss from discontinued operations, net of tax	(6.2)	(6.3)	(407.1)	0.1	0.1
Net income (loss) from continuing operations	**(2.8)**	**0.9**	**5.2**	**13.2**	**9.2**
Adjustments:					
Interest income	(0.3)	(0.1)	(0.6)	(0.7)	(0.1)
Interest expense	8.0	8.0	0.9	0.7	0.7
Income tax provision (benefit)	(1.0)	7.3	(0.5)	(3.0)	3.4
Depreciation	5.1	5.0	5.1	5.9	6.2
Amortization of intangible assets	9.4	9.0	8.9	10.6	10.4
Restructuring related charges	-	-	0.3	-	-
Loss on extinguishment of debt	9.1	-	5.3	-	-
EBITDA-from Continuing Operations	**27.4**	**30.2**	**24.6**	**26.7**	**29.8**
Non-GAAP adjustments:					
Stock-based compensation	5.1	5.3	4.9	4.4	4.2
Restructuring charges	0.4	0.3	1.2	0.6	0.6
Merger and acquisition costs / Other	0.0	0.2	0.1	0.2	0.3
Adjusted EBITDA - from Continuing Operations	**32.9**	**35.9**	**30.9**	**31.9**	**34.8**

© 2019 Brooks Automation, Inc. • Proprietary Information